RAB3D

Across TCGA pan-cancer cohorts, RAB3D Mutation is linked to patient survival in 6 of 34 cancer types, making it a survival-associated RAB3D data layer compared with 28 for mass-spec protein and 6 for mass-spec protein.

The strongest signal is observed in lymphoid neoplasm diffuse large b-cell lymphoma (DLBC), where higher RAB3D Mutation is associated with worse overall survival. In most high-consensus cancer types, elevated RAB3D expression acts as an unfavorable survival marker.

DLBC, HNSC, and MESO are the cancer types where RAB3D Mutation most reproducibly stratifies survival.

Mutation survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
DLBC	OS	Median	II,III,IV	0.172	0.949	<.001	30	view →
HNSC	OS	Median	All	0.230	0.686	.023	30	view →
MESO	DFS	Median	III,IV	0.078	0.376	.012	9	view →
LIHC	OS	Median	All	0.167	0.688	.035	6	view →
STAD	DFS	Median	All	0.211	0.709	.015	3	view →
SKCM	DFS	Median	III,IV	0.087	0.647	.013	3	view →

Pink = unfavorable, green = favorable. Showing the 6 strongest of 6 lineages.

RAB3D–DLBC (OS)

Open the DLBC breakdown →